Clinical Trial Update: Doxorubicin Hydrochloride, Cyclophosphamide, and Pacltaxel With or Without Trastuzumab in Treating Women With HER2-Positive Node-Positive or High-Risk Node-Negative Breast Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating doxorubicin, cyclophosphamide, and paclitaxel with or without trastuzumab in HER2-positive breast cancer; study completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• CYCLOPHOSPHAMIDE (Cyclophosphamide)
• DOXORUBICIN HYDROCHLORIDE (Doxorubicin hydrochloride)
• PACLITAXEL (PACLITAXEL)
• Trastuzumab (trastuzumab)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Breast Adenocarcinoma, HER2 Positive Breast Carcinoma | Phase 3 | Status: COMPLETED